Search

Displaying results 2171 - 2180 of 9667 in total
  1. Drug

    Ioxaglic acid

    go.drugbank.com/drugs/DB09313
    ApprovedWithdrawn

    Ioxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. … Ioxaglic acid has a low osmolarity and is associated with fewer side effects compared to older contrast agents [L1883].

  2. Drug

    Dimetindene

    go.drugbank.com/drugs/DB08801
    ApprovedInvestigational

    Dimetindene (Fenistil) is an antihistamine/anticholinergic used orally and locally as an antipruritic.

    Categories: Antihistamines, Anesthetics, Etc.
  3. Drug

    DL-alpha tocopheryl acetate

    go.drugbank.com/drugs/DB14477
    Approved

    Mixtures: Children's Chew Multi & Min Tab, SetonET-ECCategories: Vitamin E
  4. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

  5. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: E-Z Cups, PMS-phosphates SolutionProducts: BT ORAL SOLUSYON 45 ML, BT ORAL SOLUSYON 90 ML
  6. Drug

    Nevirapine

    go.drugbank.com/drugs/DB00238
    ApprovedInvestigational

    A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyr...

    Mixtures: Zidovex LN (Lamivudine 150mg, Zidovudine 300mg, Nevirapine 200mg Tablets)Synonyms: 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
  7. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    It consists of a radionuclide, [lutetium Lu-177], linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer. … [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate

  8. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and … [A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore

  9. Drug

    Tubocurarine

    go.drugbank.com/drugs/DB01199
    ApprovedWithdrawn

    [A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen. … [A216038] Tubocurarine's clinical use was limited by its relatively long duration of action (30-60 minutes)[A216038] and a number of significant side effects.

  10. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic T cells to lyse the cells, such as melanocytes.

    Categories: Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager